Labcorp® Tissue Complete, a
comprehensive genomic profiling service, now available in
Geneva and Shanghai to support global clinical
trials
Company expands leadership in liquid biopsy
comprehensive genomic profiling for solid tumors with the
integration of OmniSeq® INSIGHT circulating tumor DNA
BURLINGTON, N.C., June 3, 2024
/PRNewswire/ -- Labcorp (NYSE: LH), a global leader of
innovative and comprehensive laboratory services, today announced
new strategic service offerings within its precision oncology
portfolio. The enhancements strengthen Labcorp's leadership as a
premier, single-source partner for biopharmaceutical companies in
advancing cancer research and patient care both in the United States and globally.
"Labcorp's portfolio expansion enhances our integrated service
offerings and empowers our partners with the support and solutions
they need to advance their therapeutic development programs," said
Shakti Ramkissoon, M.D., Ph.D., MBA, vice president, medical lead
for oncology at Labcorp. "Combined, this can make a lasting
difference in patients' lives and health outcomes."
Bringing global expertise to comprehensive genomic
profiling
Labcorp Tissue Complete, which is powered by the
FDA-cleared and CE-marked PGDx elio™ tissue complete assay, is a
comprehensive genomic profiling (CGP) service for research and
investigational use. The offering leverages the global reach of
Labcorp's central laboratories, standardizing multi-site
biomarker-directed patient testing. Labcorp's standardized approach
reduces variability, which can result from different chemistries,
workflows and data analysis pipelines.
This expansion will extend availability of the service through
owned laboratories in Geneva and
Shanghai to support research and
investigational use in global clinical trials, streamlining access
for patients to oncology clinical trials, broadening the patient
population, and helping improve logistical efficiencies through
Labcorp's global network.
Expanding OmniSeq INSIGHT for ctDNA
Labcorp also
expands its leadership in liquid biopsy CGP for solid tumors by
adding OmniSeq INSIGHT circulating tumor DNA (ctDNA) into its
portfolio of CGP services. This new offering, complements OmniSeq
INSIGHT by evaluating the same set of key biomarkers, enabling
delivery of integrated and uniform genomic variants, tumor
mutational burden (TMB) and microsatellite instability (MSI)
detection from blood and tissue specimens to support exploratory
and longitudinal biopharmaceutical studies.
To learn about Labcorp's oncology solutions, visit
https://oncology.labcorp.com/biopharma-partners.
About Labcorp
Labcorp (NYSE: LH) is a global
leader of innovative and comprehensive laboratory services that
helps doctors, hospitals, pharmaceutical companies, researchers and
patients make clear and confident decisions. We provide insights
and advance science to improve health and improve lives through our
unparalleled diagnostics and drug development laboratory
capabilities. The company's more than 67,000 employees serve
clients in approximately 100 countries, provided support for 84% of
the new drugs and therapeutic products approved in 2023 by the FDA,
and performed more than 600 million tests for patients around the
world. Learn more about us at www.labcorp.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-new-strategic-service-offerings-within-precision-oncology-portfolio-302161441.html
SOURCE Labcorp